Table of Content

Executive Summary
Scope and Definition
Market/Product Definition
Inclusion and Exclusion
Key Questions Answered
Analysis and Forecast Note

1. Global Metastatic Prostrate Cancer Market: Industry Outlook
1.1 Introduction
1.2 Market Trends
1.3 Epidemiology Analysis
1.4 Regulatory Framework
1.5 Ongoing Clinical Trials
1.6 Market Dynamics
1.6.1 Impact Analysis
1.6.2 Market Drivers
1.6.3 Market Challenges
1.6.4 Market Opportunities

2. Global Metastatic Prostate Cancer Market (Region), ($Million), 2023-2035
2.1 North America
2.1.1 Key Findings
2.1.2 Market Dynamics
2.1.3 Market Sizing and Forecast
2.1.3.1 North America Metastatic Prostate Cancer Market, by Country
2.1.3.1.1 U.S.
2.1.3.1.2 Canada
2.2 Europe
2.2.1 Key Findings
2.2.2 Market Dynamics
2.2.3 Market Sizing and Forecast
2.2.3.1 Europe Metastatic Prostate Cancer Market, by Country
2.2.3.1.1 Germany
2.2.3.1.2 U.K.
2.2.3.1.3 France
2.2.3.1.4 Italy
2.2.3.1.5 Spain
2.2.3.1.6 Rest-of-Europe
2.3 Asia Pacific
2.3.1 Key Findings
2.3.2 Market Dynamics
2.3.3 Market Sizing and Forecast
2.3.3.1 Asia Pacific Metastatic Prostate Cancer Market, by Country
2.3.3.1.1 China
2.3.3.1.2 Japan
2.3.3.1.3 India
2.3.3.1.4 South Korea
2.3.3.1.5 Australia
2.3.3.1.6 Rest-of- Asia Pacific
2.4 Rest of the World
2.4.1 Key Findings
2.4.2 Market Dynamics
2.4.3 Market Sizing and Forecast

3. Global Metastatic Prostate Cancer Market: Competitive Landscape and Company Profiles
3.1 Key Strategies and Development
3.1.1 Mergers and Acquisitions
3.1.2 Synergistic Activities
3.1.3 Business Expansions and Funding
3.1.4 Product Launches and Approvals
3.1.5 Other Activities
3.2 Company Profiles
3.2.1 AstraZeneca
3.2.1.1 Overview
3.2.1.2 Top Products / Product Portfolio
3.2.1.3 Top Competitors
3.2.1.4 Target Customers/End-Users
3.2.1.5 Key Personnel
3.2.1.6 Analyst View
3.2.2 Merck & Co., Inc.
3.2.2.1 Overview
3.2.2.2 Top Products / Product Portfolio
3.2.2.3 Top Competitors
3.2.2.4 Target Customers/End-Users
3.2.2.5 Key Personnel
3.2.2.6 Analyst View
3.2.3 Bristol Myers Squibb
3.2.3.1 Overview
3.2.3.2 Top Products / Product Portfolio
3.2.3.3 Top Competitors
3.2.3.4 Target Customers/End-Users
3.2.3.5 Key Personnel
3.2.3.6 Analyst View
3.2.4 Daiichi Sankyo
3.2.4.1 Overview
3.2.4.2 Top Products / Product Portfolio
3.2.4.3 Top Competitors
3.2.4.4 Target Customers/End-Users
3.2.4.5 Key Personnel
3.2.4.6 Analyst View
3.2.5 Telix Pharmaceuticals
3.2.5.1 Overview
3.2.5.2 Top Products / Product Portfolio
3.2.5.3 Top Competitors
3.2.5.4 Target Customers/End-Users
3.2.5.5 Key Personnel
3.2.5.6 Analyst View
3.2.6 Exelixis
3.2.6.1 Overview
3.2.6.2 Top Products / Product Portfolio
3.2.6.3 Top Competitors
3.2.6.4 Target Customers/End-Users
3.2.6.5 Key Personnel
3.2.6.6 Analyst View
3.2.7 Eli Lilly and Company
3.2.7.1 Overview
3.2.7.2 Top Products / Product Portfolio
3.2.7.3 Top Competitors
3.2.7.4 Target Customers/End-Users
3.2.7.5 Key Personnel
3.2.7.6 Analyst View
3.2.8 Zenith Epigenetics
3.2.8.1 Overview
3.2.8.2 Top Products / Product Portfolio
3.2.8.3 Top Competitors
3.2.8.4 Target Customers/End-Users
3.2.8.5 Key Personnel
3.2.8.6 Analyst View
3.2.9 MacroGenics
3.2.9.1 Overview
3.2.9.2 Top Products / Product Portfolio
3.2.9.3 Top Competitors
3.2.9.4 Target Customers/End-Users
3.2.9.5 Key Personnel
3.2.9.6 Analyst View

4. Research Methodology

List of Figures
Figure: Global Metastatic Prostate Cancer Market (by Region), $Million, 2024 and 2035
Figure: Global Metastatic Prostate Cancer Market Supply Chain Analysis
Figure: Global Metastatic Prostate Cancer Market Key Trends, Analysis

List of Tables
Table: Global Metastatic Prostate Cancer Market, Pricing Analysis,
Table: Global Metastatic Prostate Cancer Market Dynamics, Impact Analysis
Table: Global Metastatic Prostate Cancer Market (by Region), $Million, 2024-2035